922 related articles for article (PubMed ID: 11016626)
1. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
2. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
4. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
[TBL] [Abstract][Full Text] [Related]
5. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Kismet K; Akay MT; Abbasoglu O; Ercan A
Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837
[TBL] [Abstract][Full Text] [Related]
7. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
8. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
10. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Tindall E
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Swamy MV; Patlolla JM; Steele VE; Kopelovich L; Reddy BS; Rao CV
Cancer Res; 2006 Jul; 66(14):7370-7. PubMed ID: 16849589
[TBL] [Abstract][Full Text] [Related]
13. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538
[TBL] [Abstract][Full Text] [Related]
14. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
[TBL] [Abstract][Full Text] [Related]
15. [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma].
Tuynman JB; Hulscher JB; Steller EP; van Lanschot JJ; Richel DJ
Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2207-12. PubMed ID: 14640057
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
Boolbol SK; Dannenberg AJ; Chadburn A; Martucci C; Guo XJ; Ramonetti JT; Abreu-Goris M; Newmark HL; Lipkin ML; DeCosse JJ; Bertagnolli MM
Cancer Res; 1996 Jun; 56(11):2556-60. PubMed ID: 8653697
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Harris RE; Alshafie GA; Abou-Issa H; Seibert K
Cancer Res; 2000 Apr; 60(8):2101-3. PubMed ID: 10786667
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.
Hansen-Petrik MB; McEntee MF; Jull B; Shi H; Zemel MB; Whelan J
Cancer Res; 2002 Jan; 62(2):403-8. PubMed ID: 11809688
[TBL] [Abstract][Full Text] [Related]
19. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.
Fischer SM; Lo HH; Gordon GB; Seibert K; Kelloff G; Lubet RA; Conti CJ
Mol Carcinog; 1999 Aug; 25(4):231-40. PubMed ID: 10449029
[TBL] [Abstract][Full Text] [Related]
20. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
